The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2019 | FCR treatment eligibility
Florence Cymbalista, MD, PhD, Avicenne Hospital, Bobigny, France, speaks on patient eligibility for fludarabine cyclophosphamide rituximab (FCR) treatment and the hurdles that must be overcome in order to better tailor treatment to individuals. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
